Full text
PDFPage A395
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Diepgen T. L., Geldmacher-von Mallinckrodt M. Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. Arch Toxicol Suppl. 1986;9:154–158. doi: 10.1007/978-3-642-71248-7_18. [DOI] [PubMed] [Google Scholar]
- Haley R. W., Billecke S., La Du B. N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol. 1999 Jun 15;157(3):227–233. doi: 10.1006/taap.1999.8703. [DOI] [PubMed] [Google Scholar]
- Mackness B., Durrington P. N., Mackness M. I. Human serum paraoxonase. Gen Pharmacol. 1998 Sep;31(3):329–336. doi: 10.1016/s0306-3623(98)00028-7. [DOI] [PubMed] [Google Scholar]
- Mackness B., Mackness M. I., Arrol S., Turkie W., Durrington P. N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997 Sep;122(2):265–268. doi: 10.1038/sj.bjp.0701390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miller C. S. Chemical sensitivity: symptom, syndrome or mechanism for disease? Toxicology. 1996 Jul 17;111(1-3):69–86. doi: 10.1016/0300-483x(96)03393-8. [DOI] [PubMed] [Google Scholar]
- Rowat S. C. Integrated defense system overlaps as a disease model: with examples for multiple chemical sensitivity. Environ Health Perspect. 1998 Feb;106 (Suppl 1):85–109. doi: 10.1289/ehp.98106s185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ziem G., McTamney J. Profile of patients with chemical injury and sensitivity. Environ Health Perspect. 1997 Mar;105 (Suppl 2):417–436. doi: 10.1289/ehp.97105s2417. [DOI] [PMC free article] [PubMed] [Google Scholar]